Hoch Lynelle, President of the Cell Therapy Organization at Bristol-Myers Squibb (BMY), has demonstrated a clear selling bias in their insider transactions, with no recorded purchases across 24 reported trades. All activity has been concentrated in BMY, with total sales amounting to $153,998.15. The most notable transactions occurred on March 10, 2024, and March 10, 2026, where Lynelle executed multiple sales under transaction codes "F" (indicating open-market or private sales). The largest single sale took place on March 10, 2026, valued at $54,838.56, followed by a $49,325.43 sale on March 10, 2024. Smaller transactions, such as $16,054.71 and $12,747.56 in 2026 and $10,435.26 and $10,596.63 in 2024, suggest a pattern of periodic divestment rather than a single bulk sale.
The absence of any buy transactions—coupled with the repeated sales—indicates a consistent reduction in Lynelle’s BMY holdings over time. While some filings show transaction codes "A" (award or grant), "J" (transfer), and "M" (exercise or conversion), these entries reflect $0 value adjustments, suggesting they may involve non-monetary events like option exercises or equity grants. The lack of recent trades in the data implies no new activity beyond March 2026, leaving the overall trend firmly weighted toward disposition rather than accumulation. The transactions align with typical executive equity management, though the exclusive focus on selling distinguishes Lynelle’s activity from insiders who balance purchases with sales.
AI-assisted summary